Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xuezhikang Tablet Phase II Dose-Finding Study in Primary Hyperlipidemia
CTR20191980Phase 2Completed
- Sponsor
- Sinobioway Medicine
- Start
- Oct 2019
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Xuezhikang in familial hyperlipidemia, sponsored by Sinobioway Medicine. Started Oct 2019; status: completed.
02
Drugs
Xuezhikang
03
Conditions
familial hyperlipidemia
Beyond the preview
Go deeper on CTR20191980.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20191980.